Madrigal Pharmaceuticals (Madrigal Pharmaceuticals) Interest Expense : $-14.21 Mil (TTM As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Madrigal Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Madrigal Pharmaceuticals's interest expense for the three months ended in Mar. 2024 was $ -3.84 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-14.21 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Madrigal Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was $ -152.04 Mil. Madrigal Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $ -3.84 Mil. Madrigal Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Madrigal Pharmaceuticals Interest Expense Historical Data

The historical data trend for Madrigal Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals Interest Expense Chart

Madrigal Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-3.96

-12.71

Madrigal Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-2.34	-2.90	-3.50	-3.97	-3.84

Madrigal Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.21 Mil.

Madrigal Pharmaceuticals (NAS:MDGL) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Madrigal Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $-3.84 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-152.04 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $117.18 Mil.

Madrigal Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Madrigal Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Madrigal Pharmaceuticals (Madrigal Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (NAS:MDGL) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

YDO1:Germany

Address

200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428

Website

http://www.madrigalpharma.com

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Executives

Robert E. Waltermire	officer: Senior VP, Chief Pharma Dev.	FOUR TOWER BRIDGE, 200 BARR HARBOR DRIVE, SUITE 200, WEST CONSHOHOCKEN PA 19428
Baker Bros. Advisors Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Brian Joseph Lynch	officer: SVP and General Counsel	480 MORRIS ROAD, BLUE BELL PA 19422
William John Sibold	director, officer: President and CEO	C/O MADRIGAL PHARMACEUTICALS, INC., FOUR, TOWER BRIDGE, 200 BARR HARBOR DR STE 200, WEST CONSHOHOCKEN PA 19428
Felix Baker	director	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Raymond Cheong	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Richard S Levy	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Remy Sukhija	officer: SVP and Chief Comm'l Officer	48 PHEASANT HILL ROAD, PRINCETON NJ 08540
Alex G. Howarth	officer: Chief Financial Officer	C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Bay City Capital Llc	10 percent owner	750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111
Fred B Craves	director, 10 percent owner	750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111